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Abstract
Background: Metastatic melanoma is an untreatable cancer lacking reliable and non-invasive markers of disease
progression. Exosomes are small vesicles secreted by normal as well as tumor cells. Human tumor-derived exosomes are
involved in malignant progression and we evaluated the presence of exosomes in plasma of melanoma patients as a
potential tool for cancer screening and follow-up.
Methodology/Principal Findings: We designed an in-house sandwich ELISA (Exotest) to capture and quantify exosomes in
plasma based on expression of housekeeping proteins (CD63 and Rab-5b) and a tumor-associated marker (caveolin-1).
Western blot and flow cytometry analysis of exosomes were used to confirm the Exotest-based findings. The Exotest
allowed sensitive detection and quantification of exosomes purified from human tumor cell culture supernatants and
plasma from SCID mice engrafted with human melanoma. Plasma levels of exosomes in melanoma-engrafted SCID mice
correlated to tumor size. We evaluated the levels of plasma exosomes expressing CD63 and caveolin-1 in melanoma
patients (n = 90) and healthy donors (n = 58). Consistently, plasma exosomes expressing CD63 (5046315) or caveolin-1
(6196310) were significantly increased in melanoma patients as compared to healthy donors (2236125 and 2286102,
respectively). While the Exotest for CD63+ plasma exosomes had limited sensitivity (43%) the Exotest for detection of
caveolin-1+ plasma exosomes showed a higher sensitivity (68%). Moreover, caveolin-1+ plasma exosomes were significantly
increased with respect to CD63+ exosomes in the patients group.
Conclusions/Significance: We describe a new non-invasive assay allowing detection and quantification of human exosomes
in plasma of melanoma patients. Our results suggest that the Exotest for detection of plasma exosomes carrying tumor-
associated antigens may represent a novel tool for clinical management of cancer patients.
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Introduction
Exosomes are small endosome-derived vesicles (50–100 nm in
size), actively secreted through an exocytosis pathway normally
used for receptor discharge and intercellular cross-talk [1–3]. In
addition to major histocompatibility complex proteins (MHC I,
MHC II) and proteins involved in antigen presentation, exosomes
may carry membrane and cytosolic proteins involved in many
cellular functions [1,4]. These structures are secreted under
specific physiological conditions from different cell types such as
dendritic cells (DC), lymphocytes, mast cells and epithelial cells [5–
8]. However, release of exosomes from tumor cells is dramatically
increased and represents a constitutive process, often associated
with immunosuppressive effects [3,9,10].
The role of tumor exosomes in cancer progression is recently
emerging, although initial data pointing at these organelles as
carriers of tumor antigenic material for DC-mediated T cell cross-
priming have supported clinical attempts to use tumor exosomes as
anti-cancer vaccines [11]. However, growing evidence concerning
a vast array of suppressive effects exerted by these microvesicles on
different components of the immune system is clearly supporting
the involvement of tumor exosomes in disease progression [3,12].
In particular, we and others have recently shown that exosomes
secreted by human tumor cells of various origins are able to induce
apoptosis in activated T cells, through the expression of death
ligands (e.g. FasL, TRAIL) [9,10,13], inhibit NK functions [14,15]
and promote the generation of myeloid-derived suppressor cells
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from normal monocytes [10]. These data, together with the
reproducible evidence that exosomes of likely tumor origin can be
abundantly found in plasma and neoplastic effusions of cancer
patients [16–18] support a role of tumor exosomes in molding host
microenvironment to allow tumor growth and progression [19,20].
However, the study of the in vivo role of tumor exosomes has been
so far penalized by the lack of suitable methods to quantify exosomes
from human body fluids, particularly from plasma of cancer patients.
The aim of our study was thus to provide a method to detect and
quantify exosomes from small amount of human plasma, with the
final goal of identifying a tool for assessing the role of tumor
exosomes as potential tumor marker and prognostic factor. This
might be particularly relevant in melanoma patients, in which
sensitive and reliable serum markers are unfortunately still limited
while serum LDH (lactate dehydrogenase) levels remain the only
prognostic serum factor for assessing disease course and prognosis
[21,22]. Here, we describe an in-house ELISA that allows
quantification and characterization of exosomes from different
samples, including plasma from tumor-bearing animals and
melanoma patients, as well as from tumor cell culture supernatants.
These findings suggest that the detection of tumor exosomes in
plasma of cancer patients may represent a potential biomarker in the
clinical monitoring of tumor malignancies, in particular melanoma.
Results
Set up of in-house ELISA for exosomes quantification
Exosomes detection in vitro. The ELISA we developed is
based on the presence on exosome of proteins shared with
cytoplasmic organelles such as endosomes and lysosomes (Rab-5b
and CD63), whose membranes are not shed or recycled as for
plasma membrane structures, thus excluding the possible presence
of structures deriving from membranes shedding and disruption
[23]. Culture supernatants of melanoma cells Me501 and MeBS
were processed to obtain purified exosomes and data are shown
for Me501 cells. The Exotest (Figure 1A) was able to provide a
quantification of the exosomes present in cell culture supernatants,
being CD63+ exosomes detectable in a dose-dependent manner
(Figure 1B). The negative controls, represented by fractions
derived from pellet obtained after the 10000 g centrifugation,
exosomes purified from cell culture medium alone and by the only
secondary antibody resulted in a barely measurable optical density
(OD=0.0760.01). Intra and inter-test variability were calculated
on six replicates of the same preparation run on three different
plates and were 30% and 25%, respectively. A patent application
has been recently registered for this in-house ELISA (#US 12/
321,412; PCT/EE2009/000001) and the Exotest is currently
being standardized to reach variability comparable to
commercially available kits (HansaBiomed, O.U., Estonia).
Western blot and FACS analysis of the same purified exosome
preparations confirmed the data obtained by Exotest. In fact, Rab-
5b, Lamp-1 and to a lesser extent CD63 proteins were detectable
by WB (Figure 1C) and both Rab-5b and CD63 were also detected
by FACS on exosomes bound to latex beads (Figure 1D).
However, exosomes detection and quantification by Exotest
showed a higher sensitivity for the detection of CD63 protein
with respect to WB analysis (Figure 1C). Indeed, while at least
12.5 mg of exosome proteins were needed to properly detect both
CD63 and Rab-5b by WB, the Exotest was able to detect
exosomes starting from a minimum amount of 3 mg of purified
samples.
Plasma exosomes in SCID mice engrafted with human
melanoma. In order to verify the possibility of designing a
specific ELISA for the detection of human tumor-derived
exosomes ex vivo, we purified plasma exosomes from SCID mice
subcutaneously engrafted with human melanoma cells (Me501) 5
weeks after the engraftment. As for exosomes purified from cell
culture supernatants, exosomes isolated from mice plasma were
clearly and specifically detectable by ELISA (Figure 2A) and
FACS (Figure 2B). Exosome preparations obtained from plasma of
control SCID mice (not engrafted with human tumors) resulted in
background optical densities comparable to blank samples
(OD=0.0860.03), thus suggesting the absence of exosomes in
the immunocompromised animals and that murine exosomes do
not cross-react with human CD63 and Rab-5b.
The amount of plasma exosomes in mice engrafted with human
melanoma was quantified in relation to tumor size. Melanoma-
engrafted mice (n = 33) were sacrificed 2 to 5 weeks after the
engraftment and plasma was obtained for exosomes isolation.
Linear regression analysis showed a significant correlation between
tumor size and levels of exosomes in plasma (Figure 2D). This
results was confirmed also when Spearman correlation analysis
was applied (Spearman coefficient 0.59, P,0.001). Interestingly,
animals with very large tumors (.1000 mm3) showed amount of
plasma exosomes not as high as expected. This might be due to the
low vascularization and/or to the presence of necrotic area in the
tumor that might not shed exosomes while increasing its size.
Similar results were observed for the MeBS cell line (not shown).
These data suggest that plasma exosomes quantification may
represent a valuable biomarker to monitor tumor growth in vivo.
Tumor exosomes express caveolin-1
Since exosomes are known to represent an important and
specific route of intercellular communication [1], we reasoned that
tumor-derived exosomes may differ from circulating exosomes in
normal physiological conditions both in amount and proteins
expression. Indeed, it has been recently reported that prostasomes
(membrane vesicles secreted by prostate cancer cells) contain
caveolin-1 (Cav1), a major component of caveolae [24] and that
serum level of Cav1 is elevated in prostate cancer patients [25].
Moreover, we recently showed that Cav1 is highly expressed on
vesicular structures of endolysosomal compartment in human
melanoma cells [26].
First, we observed that Cav1 is strongly expressed on exosomes
secreted by human melanoma cells in vitro while undetectable on
both cellular extracts and exosomes from normal human cells such
as for instance primary monocyte-derived macrophages (MDM)
(Figure 3A), suggesting that Cav1 secreted in an exosome-
embedded form may be a specific feature of melanoma cells, thus
representing a potential marker for the ex-vivo analysis of tumor-
derived exosomes. Therefore, we investigated the presence of
Cav1 on exosomes obtained from plasma of SCID mice engrafted
with melanoma tumors. Cav1 was detected in exosomes
preparations derived from plasma of SCID mice engrafted with
melanoma tumors by WB (Figure 3B), FACS (Figure 3C) and
ELISA (Figure 3D) while Cav1 was undetectable in plasma-
derived exosomes from control animals (Figure 3B, 3D). In
agreement with previous results from melanoma and colo-rectal
carcinoma (CRC) patients [10,16], other tumor markers, such as
MelanA/Mart-1 for melanoma and CEA for CRC, could be used
for detecting the in vivo release of tumor exosomes in tumor-
bearing SCID mice by Exotest, with results comparable with those
obtained with Cav1. However, since melanoma may express
heterogeneous or low amount of MelanA/MART-1, especially at
metastatic levels [27,28], and CEA is present mostly in soluble
form in CRC patients serum, we considered Cav1 a more reliable
and reproducible tumor marker, thus the Exotest was further
developed with the inclusion of anti-Cav1-specific antibodies.
Plasmatic Exosomes in Melanoma
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Quantification and significance of exosomes in plasma of
patients with melanoma
The data obtained in the human tumor-SCID mouse model
prompted us to investigate whether the Exotest allowed the
detection and characterization of exosomes purified from human
plasma. Since human plasma may contain structures named
microvesicles larger than exosomes, we first compared the Exotest
reactivity of microvesicles and exosomes purified from the same
plasma of 5 melanoma patients (n = 5). The Exotest revealed that
while purified exosomes were captured and expressed both CD63
and Cav1, purified microparticles showed very low reactivity
towards these two antigens (Figure S1).
Figure 1. Detection of exosomes purified from cell culture supernatants of human melanoma cells. (A) Schematic representation of the
ELISA (Exotest) set up for exosomes detection and quantification. (B) Dose-escalation analysis of purified CD63+ exosomes by Exotest. The initial
concentration corresponded to 50 mg of exosomes and exosomes were added in two-fold dilutions. (C) Western blot analysis of CD63, Rab-5b and
Lamp-1 expression in different amount of exosomes purified from culture supernatants of human melanoma cells (Me501). (D) FACS analysis of Rab-
5b and CD63 expression on melanoma-derived exosomes purified from the supernatant of Me501 cells and coated to latex beads.
doi:10.1371/journal.pone.0005219.g001
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Figure 2. Detection of plasma exosomes of SCID mice engrafted with human melanoma. (A) Dose-escalation analysis of tumor exosomes
purified from plasma of SCID mice engrafted with human melanoma cells by Exotest. (B) FACS analysis of Rab-5b and CD63 expression in exosomes
purified from plasma of SCID mice engrafted with human melanoma cells (Me501). (C) Regression analysis between plasma levels of CD63+
exosomes and tumor size in 33 mice sacrificed 2–5 weeks after engraftment with Me501 cells.
doi:10.1371/journal.pone.0005219.g002
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Exosomes were purified from plasma of tumor patients (n = 90)
and healthy donors (n = 58) and quantified by Exotest based on the
expression of CD63 and Cav1 (Table 1). As depicted in figure 4,
the Exotest allowed the detection of exosome in plasma samples
from both melanoma patients and healthy donors. However,
plasma exosomes concentration was significantly higher in
melanoma patients with respect to healthy individuals (P,0.001
for both CD63+ and Cav1+ exosomes). Interestingly, paired T-test
showed that plasma levels of Cav1+ exosomes were significantly
higher than levels of CD63+ exosomes in melanoma patients
(P=0.004).
In order to determine sensitivity and specificity of the Exotest
based on the detection of the two exosomes protein markers, we
calculated the cut-off both CD63 and Cav1-expressing plasma
exosomes. The cut-off for CD63+ exosomes and Cav1+ exosomes
was set at 2 times the standard deviations above the mean normal
exosomes plasma level in the healthy controls, which was 473 and
432 (OD45061000), respectively for CD63+ exosomes and Cav1+
exosomes. Accordingly, all samples with values above the cut-off
were considered positive while samples with values below the cut-
off were considered negative. The formulae for calculation of
sensitivity and specificity are as follows. Specificity: (number of
healthy controls with values below the cut-off / total number of
healthy controls)6100. Sensitivity: (number of patients with values
above the cut-off / total number of patients)6100. With these cut-
off values, the specificity of the Exotest for detection of CD63+
plasma exosomes and Cav1+ plasma exosomes was 96.5% and
96.3%, respectively. However, while Exotest for CD63+ plasma
exosomes showed a low sensitivity (43%) the Exotest for Cav1+
plasma exosomes had a higher sensitivity (69%).
These results suggest that i) circulating Cav1 may be associated
to exosomes in melanoma patients and ii) quantification of plasma
exosomes bearing Cav1 may be considered a useful tumor marker.
In addition, we found that serum LDH did not correlate with
either CD63+ or Cav1+ plasma exosomes while a significant
correlation was observed between CD63+ and Cav1+ plasma
exosomes (Spearman coefficient 0.32, P= 0.001). Moreover, the
Exotest revealed the presence of tumor antigens, such as MART-1
or CEA in the plasma of melanoma patients (Figure S2),
suggesting that plasma exosomes recovered from patients plasma
are likely derived from tumor cells.
Most patients included in the analysis (82/90) were affected by
advanced disease (stage III–IV). Besides six patients with very high
serum LDH and poor prognosis, LDH levels at the time of plasma
collection for exosome quantification were among the normal
range (table 1). Nevertheless, a wide distribution of plasma levels of
exosomes was detected by Exotest in all disease stages, suggesting
that the variability in the amount of exosomes present in
peripheral circulation of different patients may reflect diverse
levels of tumor aggressiveness and may become a novel
independent prognostic factor for melanoma. Other prognostic
factors indicated by the American Joint Committee on Cancer
Figure 3. Characterization of caveolin-1 expression on exosomes. (A) Western blot analysis of Cav1 in cellular extracts and exosomes from
human melanoma cells and macrophages (W). (B) Western blot analysis of CD63, Rab-5b and Cav1 in purified exosomes from Me501 cells, plasma of
Me501-engrafted SCID mice and tumor-negative SCID mice. (C) FACS analysis of Cav1 expression on exosomes purified from plasma of Me501-
engrafted SCID mice. (D) Plasma levels of CD63+ and Cav1+ exosomes from melanoma-bearing SCID mice sacrificed 5 weeks after engraftment.
doi:10.1371/journal.pone.0005219.g003
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(AJCC), including primary melanoma thickness and ulceration,
number of metastatic lymph nodes, and site and number of distant
metastases, might also correlate with exosomes serum content, as
suggested by the data in mice engrafted with human melanoma, in
which exosomes amount was directly associated with tumor
burden. However, the relatively limited number of patients
enrolled in this study does not allow presently to reach any
statistical significance in the analysis.
Use of whole plasma for exosomes quantification
The potential applications of Exotest for clinical purposes
prompted us to verify whether this assay could be utilized for
exosomes detection in unfractioned biological fluids that would
allow an easier and more reproducible analysis avoiding the steps
of ultracentrifugation. Therefore, we compared the detection and
quantification of CD63+ exosomes from unfractioned samples (cell
culture supernatants from human macrophages and melanoma
cells, and human plasma) and exosomes purified from the same
samples. In order to increase the sensitivity of the test, for these
specific experiments the HRP-conjugated Mab was incubated for
30 minutes instead of 15 minutes. As shown in figure 5A, the
presence of exosomes from unfractioned macrophages and
melanoma culture supernatants and plasma from 9 melanoma
patients was detectable by Exotest. In addition, we performed the
same analysis on plasma from 4 healthy donors and regression
analysis on the total number of samples analysed (9 patients+4
healthy donors) showed a significant correlation between the two
types of measures (Figure 5B). These results suggest the potential
application of the Exotest in clinical settings using whole plasma
and avoiding the complex and time consuming procedure of
exosomes purification.
Discussion
In this study we describe an in-house ELISA to detect and
quantify exosomes from cell culture supernatants and human
plasma, named Exotest. Exosomes are microvesicles produced by
virtually all cells, but their secretion is known to be constitutively
exacerbated in tumor cells, and several groups including ours,
have reported the presence of exosomes of likely tumor origin in
plasma and other biological fluids from cancer patients [10,16–
18,29]. Although exosomes are implicated in a vast array of
cellular functions, and have been considered a cell-free source of
tumor antigens when secreted by cancer cells [11,18], they have
been lately hypothesized to foster immunosuppression in tumor-
bearing hosts [3,9,12,16,30]. Recently, it was shown that the
ability of serum exosomes from HNC patients to induce T-cell
apoptosis correlated with disease activity and the presence of
lymph node metastases [19]. Because of their potential involve-
ment in promoting disease progression through a series of
detrimental effects on tumor microenvironment, the possibility of
quantifying exosomes in human plasma or serum is recently
becoming an important issue. Such an assay would represent a
fundamental tool for assessing the potential role of these
microvesicles in cancer progression, and as a prognostic factor in
the follow-up of cancer patients. Currently used methods for
exosomes analysis and studies on their protein content include
western blot, flow cytometry and mass spectrometry [1]. The
quantitative method we describe here is instead based on ELISA-
mediated detection of exosomes and represents to our knowledge
the first report about an easy and reliable assay for exosome
quantification. The proteins that are detected by our Exotest are
not exosome-specific but are exclusively shared with cytoplasmic
organelles, such as endosomes and lysosomes (Rab-5b and CD63),
whose membranes are not recycled as for plasma membrane
structures [1].
This excludes the possibility of detecting these proteins on
plasma microparticles or debris derived from necrotic tumor cells,
or in their soluble form. The assay we developed also included a
tumor marker (caveolin-1) which allows the preferential detection
of tumor-secreted exosomes. A series of comprehensive studies
performed by different comparative methods (such as WB and
FACS) and in different experimental conditions (supernatants
Figure 4. Quantification of exosomes in plasma from melano-
ma patients. Exosomes purified from plasma of healthy donors and
melanoma patients were quantified by Exotest using as detection
antigens CD63 (A) or caveolin-1 (B). Data are expressed as box plot
representation: the horizontal and vertical lines in each box represent
the median and the 25th–75th percentiles, respectively; black dots
represent outlier values. Differences between groups were evaluated by
Mann-Whitney test and are reported in the text.
doi:10.1371/journal.pone.0005219.g004
Table 1. Plasma exosomes and serum LDH levels in the study
population.
CD63+ exo Cav1+ exo LDH
Melanoma patients (n =90) 5046315 6196310 4716458
Healthy donors (n=58) 2236125 2286102 3606345
CD63+ exo and Cav1+ exo are plasma exosomes (expressed as OD45061000).
Plasma LDH values are expressed as IU/L. Data are expressed as mean6SD.
doi:10.1371/journal.pone.0005219.t001
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from melanoma vs normal cells, and plasma from normal vs
melanoma-engrafted SCID mice) proved the reliability of the
Exotest. Moreover, we found that cell lines of other tumor
histotypes (osteosarcoma and CRC) secreted exosomes expressing
variable levels of CD63 and Cav1 (Figure S2), in line with the
reported cellular expression of Cav1 in these cancers [31,32].
Using this assay, we observed that significantly increased amounts
of exosomes expressing tumor markers such as caveolin-1 are
present in plasma from melanoma patients with respect to healthy
individuals. Interestingly, the wide distribution of Cav1+ plasma
exosomes within the patients’ population suggests the potential use
of exosomes in plasma as prognostic marker. In fact, plasma levels
of Cav1-expressing exosomes were significantly decreased in
patients undergoing chemotherapy with respect to patients
untreated at time of sampling (data not shown). Since this was a
cross-sectional analysis of patients undergoing diverse chemother-
apy regimens, longitudinal studies on patients undergoing strictly
controlled chemotherapy protocols will better define the impor-
tance of this observation. It should be underlined that exosomes
are also detected in normal subjects, being secreted also by normal
cells of different organs, including blood cells. However, the levels
of exosomes quantified in plasma of melanoma patients are
significantly above the cut-off level calculated from healthy donors,
suggesting a good level of sensitivity and a high specificity of
detection. Recently, it has been reported that plasma exosomes of
melanoma patients promote the generation of suppressive myeloid
cells [10] and the induction of a series of different functional
defects in activated T cells [9,16,33], suggesting that tumor cells
Figure 5. Exotest on unfractioned samples. (A) The amount of detectable exosomes was measured in purified exosomes (50 mg), unfractioned
culture supernatants (50 ml) from human macrophages, melanoma cells and plasma from melanoma patients. Data are expressed as means6SD. (B)
Regression analysis of plasma levels of CD63+ exosomes measured in purified or unfractioned plasma samples from both patients (n = 9, black
diamonds) and healthy donors (n = 4, white diamonds). Exosomes levels are expressed as OD45061000.
doi:10.1371/journal.pone.0005219.g005
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may use exosomes to damage the immune system without a direct
interaction with immune cells. Moreover, it is progressively
emerging that these vesicles can be used by tumor cells as a
non-cellular tool for microenvironment remodelling, promotion of
neo-angiogenesis, and sustainment of their own growth through
autocrine loop [3,12]. Interestingly, human prostate cancer cells
secreting caveolin-1 induced tumor growth of caveolin-1 negative
tumor cells in vivo through the release of caveolin-1 associated to
lipoprotein particles [34]. The selective and/or preferential
expression of caveolin-1 on exosomes from tumor patients may
thus represent an important marker of malignant progression and
deserves further investigation about its possible application as a
screening method in tumor patients. Notably, this is the first
evidence that caveolin-1 is expressed on exosomes released by
human tumors.
An alternative and more intriguing hypothesis is that exosomes
could be a hallmark of more aggressive tumors, and thus high
exosomes plasma levels could identify patients with unfavorable
prognosis despite early disease stage. Indeed, the unique
biochemical properties of these organelles and the peculiar lipid
composition of their membranes may determine their long-term
persistence in plasma also in patients whose tumor has been
surgically removed [30]. Because of the lack of a reliable
quantitative assay, no study has so far addressed whether the
amount of exosomes in plasma may associate with a different
disease course in cancer patients. This is an even more important
issue in melanoma, which is a rather heterogeneous disease, with
subsets of patients undergoing unexpectedly poor prognosis
despite the presence of good prognostic factors and vice versa.
Melanoma is still one of the cancers in which a soluble tumor
marker in support of prognosis and treatment evaluation has not
yet been identified [35]. Our results suggest that an exosome-
specific ELISA may be used for detection and quantification of
circulating exosomes in melanoma patients. Moreover, the test
offers the possibility of detecting different proteins in plasma
exosomes preparations, with the potential application to specific
type of tumor patients. We reckon that longitudinal clinical studies
on larger cohorts and standardization of the method described are
to be performed in order to evaluate whether plasma exosomes
quantification and characterization may represent an independent
prognostic factor for melanoma patients and possibly for patients
carrying other types of cancers. Nevertheless, this assay may help
exploring a rather new field in cancer research for the
identification of novel prognostic tools for cancer.
Methods
Cell culture
We used two human metastatic melanoma cell lines (Me501
and MeBS) obtained from metastatic melanoma lesions of patients
(Istituto Nazionale Tumori, Milan, Italy). Tumor cells were
negative for Mycoplasma contamination as routinely tested by
PCR (VenorHGeM, Minerva Biolabs, Germany). Cell lines were
cultured in RPMI 1640 medium supplemented with antibiotics
and 10% fetal calf serum (FCS) (Invitrogen, Milan, Italy)
previously depleted from bovine microvesicles by ultracentrifuga-
tion (100,0006g for 90 minutes). Human monocytes-derived
macrophages (MDM) were obtained from buffy coats of healthy
blood donors by using CD14 magnetic beads ((Miltenyi Biotec,
Germany) and GM-CSF (500 U/ml) for 5 days in culture.
The osteosarcoma (SaOS-2) and colon carcinoma (Colo 1869)
cell lines were a kind gift of Dr. Maccalli (San Raffaele Scientific
Institute, Milano) and Dr. Serra (Istituti Ortopedici Rizzoli,
Bologna).
Exosomes purification from cell culture supernatants and
plasma
Supernatants from human melanoma cell lines were harvested
from 72 hs 70–75% confluent cell cultures in 175 cm2 flasks and
were isolated as previously described [36,37]. Briefly, after
centrifugation of cells at 300 g for 10 minutes, supernatants were
centrifuged at 1,200 g for 20 minutes followed by 10,000 g for
30 minutes. Supernatants were filtered using a 0.22 mm filter
(Millipore Corp., Bedford, MA) and centrifuged at 100,000 g for
1 h in a Beckman ultracentrifuge (Beckman Coulter) in order to
pellet exosomes. After 1 wash in a large volume of phosphate-
buffered saline (PBS), exosomes were resuspended in PBS (50–
100 ml) or in lysis buffer, and stored at 280uC for experimental
analysis.
In order to obtain exosomes from plasma samples, EDTA-
treated blood from SCID mice engrafted with human melanoma
or plasma from tumor patients and healthy donors were
centrifuged at 400 g for 20 minutes. Plasma was then collected
and stored at270uC until analysis. Plasma samples were subjected
to the same centrifugal procedure described above to isolate
exosomes. In addition, for some samples the pellet recovered after
the centrifugation at 10,000 g for 30 minutes representing
microparticles was collected and analysed.
ELISA for exosomes detection
Ninety-six well-plates (Nunc, Milan, Italy) were coated with
polyclonal 4 mg/ml anti-Rab-5b antibody (clone A-20, Santa
Cruz) in a volume of 100 ml/well of carbonate buffer (pH 9.6) and
incubated overnight at 4uC. After 3 washes with PBS, 100 ml/well
of blocking solution (PBS containing 0.5% BSA) were added at
room temperature for 1 hour. Following 3 washes in PBS,
exosomes purified from cell culture supernatants or from plasma
were added in a final volume of 50 ml and incubated overnight at
37uC. After 3 washes with PBS, anti-CD63 Mab (clone H5C6,
Pharmingen) or anti-caveolin-1 Mab (clone 2297, Pharmingen)
diluted 4 mg/ml were added and incubated for 1 hour at 37uC.
After 3 washes with PBS, the plate was incubated with 100 ml of
HRP-conjugated anti-mouse antibody (Pierce, Milan, Italy)
diluted 1:50,000 in blocking solution for 1 hour at room
temperature. After the final 3 washes with PBS, the reaction was
developed with POD for 15 min (Roche Applied Science, Milan),
blocked with H2SO4 and optical densities were recorded at
450 nm.
Flow cytometry analysis of exosomes
Exosome preparations (5–10 mg) were incubated with 5 ml of 4-
mm-diameter aldehyde/sulfate latex beads (Interfacial Dynamics,
Portland, OR) and resuspended into 400 ml PBS containing 2%
FCS. Exosomes-coated beads (20 ml) were incubated with the
following antibodies: anti-CD63-FITC (Pharmingen), anti-CD81-
PE (Pharmingen), anti-Rab5b (Santa Cruz), anti-caveolin-1 (clone
N-20, Santa Cruz) for 30 minutes at 4uC, followed, when needed,
by incubation with PE- or FITC-conjugated secondary antibody
and analyzed on a FACSCalibur flow cytometer (BD Biosciences).
Western blot analysis of exosomes
Purified exosomes or cells were treated with lysis buffer (1%
Triton X-100, 0,1% SDS, 0.1 M Tris HCl, pH 7) and protease
inhibitors (Sigma) and protein concentration was determined by
Bradford microassay (Bio-Rad Laboratories, Hercules, CA).
Proteins were separated on 10% SDS-PAGE gel and transferred
to nitrocellulose membranes. Membranes were blotted with
antibodies to CD63 and Lamp-1 (Mabs, Pharmingen), Rab-5b
Plasmatic Exosomes in Melanoma
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and caveolin-1 (polyclonal antibodies, Santa Cruz), incubated with
appropriate HRP-conjugated secondary antibodies (Amersham
Pharmacia) and visualised by enhanced chemiluminescence
(Pierce).
Human tumor SCID-mouse model
CB.17 SCID/SCID female mice (Harlan, Milano, Italy) were
used at 4–5 weeks of age and kept under specific pathogen-free
conditions. Animal care was conformed to the European Council
Directive 86/609/EEC and the study was approved by the
institutional review board. Mice were injected subcutaneously into
the right flank with 2.56106 human melanoma cells and tumour
weight was measured by a caliper with the formula: Tumor size
(mm3) = length6width2 /2 [38]. Five-hundred ml of blood from
tumor-engrafted mice were collected from different animals
sacrificed at different time-points during tumor growth.
Melanoma patients
Human plasma samples were collected from EDTA-treated
whole blood from patients with melanoma (n= 90) attending the
Istituto Nazionale dei Tumori (Milan) and the Ospedale Le Scotte
(Siena) and age and sex-matched healthy donors (n = 58) and
stored at 270uC until analysis. The study was approved by the
local ethical committees and patients gave written informed
consent to participate.
Statistical analysis
Statistical analyses were performed by using the software
SigmaStat (SPSS Inc.). Differences between melanoma patients
and healthy donors were analysed by Mann-Whitney test,
Wilcoxon signed rank paired test or student T test as appropriate.
Correlation between variables was assessed by Spearman rank test
or regression analysis. Data in the text are expressed as mean6SD.
All P values reported are two-sided.
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